Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Phase 2 Trial of Smoldering and Active MM
2024-519353-11-00Phase 2Authorised
- Sponsor
- Landspitali
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) and smoldering multiple myeloma (SMM), sponsored by Landspitali. Primary endpoint: Proportion of MRD-negative participants at 3 years. Planned start Dec 2024; status: authorised.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2024-519353-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519353-11-00.